Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis

Authors: Carcao, M., Shapiro, A., Hwang, N., Pipe, S., Ahuja, S., Lieuw, K., Staber, JM., Belletrutti, M., Sun, HL., Ding, H., Wang, M., Price, V., Steele, M., Tsao, E., Feng, J., Al-Khateeb, Z., Dumont, J., and Jain, N.

Publication: Haemophilia; November 2020

Affiliations: The Hospital for Sick Children, Toronto, ON, Canada; Indiana Hemophilia & Thrombosis Center, Inc, Indianapolis, IN, USA; Center For Inherited Blood Disorders, Orange, CA, USA; University of Michigan, Ann Arbor, MI, USA; University Hospitals Rainbow Babies & Children’s Hospital, Cleveland, OH, USA; Walter Reed National Military Medical Center, Bethesda, MD, USA; University of Iowa Stead Family Children’s Hospital, Iowa City, IA, USA; University of Alberta Stollery Children’s Hospital, Edmonton, AB, Canada; University of Alberta Hospital, Edmonton, AB, Canada; Rady Children’s Hospital, San Diego, CA, USA; Hemophilia and Thrombosis Center, University of Colorado, Aurora, CO, USA; IWK Health Centre, Halifax, NS, Canada; Alberta Children’s Hospital, Calgary, AB, Canada; Sanofi, Waltham, MA, USA ; Trinity Partners LLC, Waltham, MA, USA; Sanofi, Cambridge, MA, USA

Abstract: No abstract available